These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P Front Immunol; 2020; 11():372. PubMed ID: 32210968 [TBL] [Abstract][Full Text] [Related]
3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905 [TBL] [Abstract][Full Text] [Related]
5. CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy. Chen H; Fu T; Suh WK; Tsavachidou D; Wen S; Gao J; Ng Tang D; He Q; Sun J; Sharma P Cancer Immunol Res; 2014 Feb; 2(2):167-76. PubMed ID: 24778280 [TBL] [Abstract][Full Text] [Related]
6. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis. Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026 [TBL] [Abstract][Full Text] [Related]
7. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267 [TBL] [Abstract][Full Text] [Related]
8. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021 [TBL] [Abstract][Full Text] [Related]
10. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8 Wang K; Coutifaris P; Brocks D; Wang G; Azar T; Solis S; Nandi A; Anderson S; Han N; Manne S; Kiner E; Sachar C; Lucas M; George S; Yan PK; Kier MW; Laughlin AI; Kothari S; Giles J; Mathew D; Ghinnagow R; Alanio C; Flowers A; Xu W; Tenney DJ; Xu X; Amaravadi RK; Karakousis GC; Schuchter LM; Buggert M; Oldridge D; Minn AJ; Blank C; Weber JS; Mitchell TC; Farwell MD; Herati RS; Huang AC Cancer Cell; 2024 Sep; 42(9):1582-1597.e10. PubMed ID: 39214097 [TBL] [Abstract][Full Text] [Related]
11. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. De Henau O; Rausch M; Winkler D; Campesato LF; Liu C; Cymerman DH; Budhu S; Ghosh A; Pink M; Tchaicha J; Douglas M; Tibbitts T; Sharma S; Proctor J; Kosmider N; White K; Stern H; Soglia J; Adams J; Palombella VJ; McGovern K; Kutok JL; Wolchok JD; Merghoub T Nature; 2016 Nov; 539(7629):443-447. PubMed ID: 27828943 [TBL] [Abstract][Full Text] [Related]
12. Berberine sensitizes immune checkpoint blockade therapy in melanoma by NQO1 inhibition and ROS activation. Luo Z; Li Q; He S; Liu S; Lei R; Kong Q; Wang R; Liu X; Wu J Int Immunopharmacol; 2024 Dec; 142(Pt A):113031. PubMed ID: 39217888 [TBL] [Abstract][Full Text] [Related]
14. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. Slovak RJ; Park HJ; Kamp WM; Ludwig JM; Kang I; Kim HS Sci Rep; 2021 Mar; 11(1):6956. PubMed ID: 33772035 [TBL] [Abstract][Full Text] [Related]
16. IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses. Qu Q; Zhai Z; Xu J; Li S; Chen C; Lu B Front Immunol; 2020; 11():634. PubMed ID: 32351508 [TBL] [Abstract][Full Text] [Related]
17. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H Front Immunol; 2021; 12():793831. PubMed ID: 34987517 [TBL] [Abstract][Full Text] [Related]
18. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649 [TBL] [Abstract][Full Text] [Related]
19. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer. Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241 [TBL] [Abstract][Full Text] [Related]